SRTA - Strata Critical Med... Stock Analysis | Stock Taper
Logo
Strata Critical Medical, Inc.

SRTA

Strata Critical Medical, Inc. NASDAQ
$4.18 -2.34% (-0.10)

Market Cap $369.65 M
52w High $6.02
52w Low $2.35
P/E -9.95
Volume 673.87K
Outstanding Shares 86.37M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $49.3M $17.24M $57.42M 116.47% $-0.04 $-9.24M
Q2-2025 $70.8M $22.69M $-3.74M -5.29% $-0.05 $-3.18M
Q1-2025 $54.31M $19.56M $-3.49M -6.43% $-0.04 $-5.89M
Q4-2024 $54.36M $20.96M $-9.79M -18.02% $-0.12 $-6.84M
Q3-2024 $74.88M $23.37M $-1.95M -2.61% $-0.03 $-2.26M

What's going well?

The company reported a large net profit thanks to gains from discontinued operations and a big tax benefit. No interest expense means no debt pressure.

What's concerning?

Sales dropped sharply, margins are getting squeezed, and the core business is losing money. The profit is not from normal operations, so the underlying business remains weak.

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $75.92M $335.08M $52.08M $283M
Q2-2025 $113.42M $257.92M $34.82M $223.1M
Q1-2025 $120.01M $250.55M $30.82M $219.73M
Q4-2024 $127.14M $256.68M $34.74M $221.94M
Q3-2024 $136.34M $282.94M $49.45M $233.5M

What's financially strong about this company?

SRTA has very low debt, lots of equity, and more than enough current assets to pay its bills. The company paid down debt and grew its book value sharply this quarter.

What are the financial risks or weaknesses?

Cash and investments dropped by a third, and a big jump in goodwill means more risk if acquisitions don't work out. Receivables and payables both rose fast, which could squeeze cash flow if not managed.

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.66M $-31.84M $2.4M $-7.24M $-37.3M $-34.97M
Q2-2025 $-3.74M $-4.21M $28.68M $14K $24.63M $-6.94M
Q1-2025 $-3.49M $-4.55M $20.41M $60K $16.04M $-7.7M
Q4-2024 $-9.79M $13K $3.98M $-5.64M $-1.76M $-5.03M
Q3-2024 $-1.95M $6.36M $-12.65M $-731K $-6.96M $-3.56M

What's strong about this company's cash flow?

Working capital changes provided a temporary boost to cash flow, and the company is not taking on new debt or diluting shareholders much. If the business can cut cash burn or grow revenue quickly, there's a chance to stabilize.

What are the cash flow concerns?

Cash burn jumped sharply this quarter, with $35 million in free cash flow lost and only $23 million left in the bank. Without a turnaround, the company will need to raise money soon or risk running out of cash.

Revenue by Products

Product Q3-2024Q4-2024Q1-2025Q2-2025
Medical Segment
Medical Segment
$40.00M $40.00M $40.00M $50.00M
Passenger Segment
Passenger Segment
$40.00M $20.00M $20.00M $30.00M

Revenue by Geography

Region Q3-2024Q4-2024Q1-2025Q2-2025
NonUS
NonUS
$10.00M $0 $10.00M $10.00M
UNITED STATES
UNITED STATES
$60.00M $50.00M $50.00M $60.00M

Q3 2025 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at Strata Critical Medical, Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

SRTA’s key strengths are its strong revenue growth, improving gross and operating margins, and conservative balance sheet. The company has demonstrated that it can scale sales quickly while gradually tightening its cost structure. High liquidity and low leverage provide a cushion against setbacks and give management flexibility to keep investing in growth. Rising gross profit and better operating leverage point to a business model that becomes more efficient as it grows.

! Risks

The main risks center on persistent unprofitability and cash burn. Despite revenue gains and margin improvement, the company still posts sizable operating and net losses, which have accumulated into a large negative retained earnings balance. Free cash flow is consistently negative, recently exacerbated by a surge in capital expenditures. Asset and equity levels have been drifting down from prior peaks, and cash balances are shrinking, which, if continued, could eventually constrain the company’s ability to fund operations and growth without new capital.

Outlook

Looking ahead, the trajectory is mixed but somewhat constructive. Operational trends—stronger revenue, better margins, and some narrowing of losses—suggest the business is moving toward a more sustainable model, especially if cost discipline continues. At the same time, the ongoing need for cash, increasing capital intensity, and lack of clear visibility into the competitive and innovation landscape introduce meaningful uncertainty. The company’s ample liquidity and low debt buy it time, but the medium‑term outlook will depend on whether it can convert growth and investment into durable, self‑funding profitability.